Fly News Breaks for May 22, 2015
ACT
May 22, 2015 | 07:44 EDT
JPMorgan says shares of Actavis are trading at a greater than 20% valuation to the Major Pharma space despite better organic growth prospects. The firm sees a "compelling case" for multiple expansion and reiterates an Overweight rating on Actavis with a $375 price target.
News For ACT From the Last 2 Days
There are no results for your query ACT